Elite Pharmaceuticals Inc (ELTP)

[Goodtimes93]

Variations on valuations models do not support the current market valuation without baking in a high probability of SQ approval. That being said it will require further investment and significant allotments of time to achieve this value.

What is not considered is the competition in this optimistic view. Each day of delay allows competitors to invest and get closer to parity. There is also the suggestion that competition is only from within the opioid market which is myopic at best. Pain reduction comes in many forms and the choices increase each day.

An investment here will not as a result generate a return for at a minimum 6 months. That is assuming the "path forward" yields results which is also an unknown. The opportunity cost thus is too large given the better investment alternatives. This can be revisited at a later date for changes but most likely shares will be cheaper to buy.